On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation.
When planning a clinical trial the sample size calculation is commonly based on an a priori estimate of the variance of the outcome variable. Misspecification of the variance can have substantial impact on the power of the trial. It is therefore attractive to update the planning assumptions during the ongoing trial using an internal estimate of the variance. For this purpose, an EM algorithm based procedure for blinded variance estimation was proposed for normally distributed data. Various simulation studies suggest a number of appealing properties of this procedure. In contrast, we show that (i) the estimates provided by this procedure depend on the initialization, (ii) the stopping rule used is inadequate to guarantee that the algorithm converges against the maximum likelihood estimator, and (iii) the procedure corresponds to the special case of simple randomization which, however, in clinical trials is rarely applied. Further, we show that maximum likelihood estimation leads to no reasonable results for blinded sample size re-estimation due to bias and high variability. The problem is illustrated by a clinical trial in asthma.
Friede
Tim
T
Medical Statistics Unit, Lancaster University, Fylde College, Lancaster LA1 4YF, UK. t.friede@lancaster.ac.uk
Kieser
Meinhard
M
D000280:Administration, Inhalation; D000465:Algorithms; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods*; D003198:Computer Simulation; D006801:Humans; D015233:Models, Statistical; D009330:Nebulizers and Vaporizers / Q000592:standards; D018401:Sample Size
D018927:Anti-Asthmatic Agents; D001507:Beclomethasone